Effect of lead chelation therapy with EDTA in children on erythrocyte pyrimidine 5'-nucleotidase and with cytidine triphosphate levels.
Children with elevated whole blood lead levels were treated for 4 days with EDTA. Changes in whole blood lead concentrations, erythrocyte zinc protoporphyrin concentrations, red cell pyrimidine 5'-nucleotidase activities, and erythrocyte cytidine triphosphate (CTP) levels were measured during the course of the EDTA therapy. EDTA treatment decreased blood lead levels by approximately 50% after 4 days. An inverse relationship existed between blood lead levels and erythrocyte pyrimidine 5'-nucleotidase activity. Despite reactivation of pyrimidine 5'-nucleotidase enzyme activity by EDTA, there was no decrease in erythrocyte cytidine triphosphate or in zinc protoporphyrin concentrations. The lack of change in these two parameters during EDTA treatment supports the concept that pyrimidine 5'-nucleotidase inhibition by lead in the reticulocyte cytidine phosphate accumulation in moderate lead poisoning may reflect chronic lead overburden analogous to prolonged elevation of erythrocyte zinc protoporphyrins.
D015720:5'-Nucleotidase; D002675:Child, Preschool; D003570:Cytidine Triphosphate / Q000097:blood*; D003597:Cytosine Nucleotides / Q000097:blood*; D004492:Edetic Acid / Q000627:therapeutic use*; D004912:Erythrocytes / Q000378:metabolism*; D006801:Humans; D007223:Infant; D007854:Lead / Q000097:blood; D007855:Lead Poisoning / Q000097:blood* / Q000188:drug therapy; D009708:Nucleotidases / Q000097:blood*; D011524:Protoporphyrins / Q000097:blood
D003597:Cytosine Nucleotides; D011524:Protoporphyrins; C017803:zinc protoporphyrin; D007854:Lead; D003570:Cytidine Triphosphate; D004492:Edetic Acid; D009708:Nucleotidases; D015720:5'-Nucleotidase